Trial · NCT03181503
Results by group242
Each measurement the trial posted, group by group, in the words and numbers it posted.
121 to 140 of 242
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Placebo | First injection, after 72 hours | 4.0 | Standard Deviation 1.37 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Nemolizumab 0.5 mg/kg | First injection, after 72 hours | 5.7 | Standard Deviation 1.34 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Placebo | Before Second Injection (Week 4) | 4.4 | Standard Deviation 1.07 | Units on a scale |
| Dynamic Pruritus Score (DPS) at 24, 48, and 72 Hours After First Injection and Before Second Injection (Week 4) | Nemolizumab 0.5 mg/kg | Before Second Injection (Week 4) | 6.3 | Standard Deviation 1.89 | Units on a scale |
| Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12 | Placebo | Baseline | 87.1 | Standard Error 5.42 | Prurigo Lesions |
| Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12 | Nemolizumab 0.5 mg/kg | Baseline | 84.9 | Standard Error 5.50 | Prurigo Lesions |
| Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12 | Placebo | Week 12 | 74.2 | Standard Error 6.83 | Prurigo Lesions |
| Prurigo Activity Score (PAS) Item 5: Overall Number of Prurigo Lesions at Week 12 | Nemolizumab 0.5 mg/kg | Week 12 | 54.8 | Standard Error 6.42 | Prurigo Lesions |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Day 1: Stage 0 | 0 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Day 1: Stage 0 | 0 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Day 1: Stage 1 | 2 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Day 1: Stage 1 | 4 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Day 1: Stage 2 | 7 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Day 1: Stage 2 | 5 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Day 1: Stage 3 | 14 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Day 1: Stage 3 | 12 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Day 1: Stage 4 | 13 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Day 1: Stage 4 | 13 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Placebo | Excoriation/Crusts: Week 4: Stage 0 | 2 | Participants | |
| Prurigo Activity Score (PAS) Item 6: Number of Participants With Defined Stages of Excoriation/Crusts and Healed Lesions at Each Visit | Nemolizumab 0.5 mg/kg | Excoriation/Crusts: Week 4: Stage 0 | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03181503/results?page=7